Apoquel

Apoquel is a veterinary prescription drug brand owned and commercialized by Zoetis, primarily for dogs. Its active ingredient is oclacitinib, a medicine that modulates signaling associated with allergic reactions and itch in dogs. The brand is used mainly to relieve itching associated with allergic and atopic dermatitis; it is not the same as a treatment that permanently eliminates the underlying cause of an allergy. Veterinarians determine whether it is appropriate based on the dog’s age, weight, symptoms, medical history, and local labeling. As a prescription product, its indications, contraindications, dosing, and safety information depend on the approved product information in each market.

Apoquel is a Zoetis veterinary prescription brand based on oclacitinib. It was developed for the management of itch associated with allergic and atopic dermatitis in dogs, placing the brand within the companion-animal dermatology and allergy-treatment segment. Unlike medicines aimed at infections or parasites, its principal role is to modulate signaling associated with itch and allergic responses, so veterinarians generally assess the underlying condition before prescribing it. Approval timing, approved indications, strengths, and availability vary by market. Apoquel remains part of Zoetis’s companion-animal prescription portfolio, with use governed by local labeling and veterinary direction.

Veterinary prescription for the management of allergic pruritus and dermatitis symptoms in dogs

• Apoquel

  Apoquel is a dog prescription medicine brand containing oclacitinib. It is primarily used to relieve itch associated with allergic and atopic dermatitis. It is a symptom-management veterinary product, and its indications, dosing, contraindications, and duration of use depend on local approved labeling and veterinary assessment.